US OptionsDetailed Quotes

LUNG241220C2500

Watchlist

0.00
0.000.00%

15min DelayClose Nov 27 09:30 ET

0.00High0.00Low

Pulmonx Stock Discussion

Jaguar8

Sep 9 15:30

NEWS

$Pulmonx (LUNG.US)$
Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024
Pulmonx (Nasdaq: LUNG) presented clinical data from two significant studies at the European Respiratory Society Congress 2024. The AeriSeal® CONVERT trial showed that 77.6% of patients with collateral ventilation (CV+) successfully converted to CV- status after treatment with the AeriSeal System...

Hmm

Pulmonx's balance sheet suggests it could easily eliminate its debt. Its revenue growth over the last year indicates potential profitability. However, it had an EBIT loss over the last year, with a negative free cash outflow of US$40m and a US$61m accounting loss.

Is Pulmonx (NASDAQ:LUNG) Using Debt Sensibly?

Moomoo AI

Dec 8, 2023 04:24

Insider sales of Pulmonx shares below the current price, including by Glendon French, could indicate comfort with a lower valuation. A lack of insider purchases in the past year and low insider ownership might suggest a lack of alignment between management and small shareholders.

Don't Ignore The Insider Selling In Pulmonx

👀

$Pulmonx (LUNG.US)$ buy

No comment yet